

## Pre - PA Allowance

None

---

## Prior-Approval Requirements

**Age** 18 years of age and older

### Diagnoses

Patients must have **ONE** of the following:

1. Metastatic castration-resistant prostate cancer (CRPC)
  - a. Used in combination with prednisone
2. Metastatic high-risk castration-sensitive prostate cancer (CSPC)
  - a. Used in combination with prednisone
3. Non-metastatic very-high-risk prostate cancer
  - a. Used in combination with prednisone or methylprednisolone

**AND ALL** of the following for **ALL** indications:

- a. **NO** dual therapy with another androgen receptor inhibitor (see Appendix 1)
- b. Male patients with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Zytiga and for 3 weeks after the final dose
- c. **Brand Zytiga only**: Patient **MUST** have tried the preferred product (generic Zytiga: abiraterone acetate) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

## Prior - Approval Limits

### Quantity

Strength	Quantity
250 mg	360 tablets per 90 days <b>OR</b>
500 mg	180 tablets per 90 days

**Duration** 12 months

---

## Prior – Approval *Renewal* Requirements

Same as above



Federal Employee Program.

**ZYTIGA**  
(abiraterone acetate)

## Prior - Approval *Renewal* Limits

Same as above

---

### Appendix 1 - List of Androgen Receptor Inhibitors

Generic Name	Brand Name
abiraterone	Yonsa
abiraterone	Zytiga
apalutamide	Erleada
darolutamide	Nubeqa
enzalutamide	Xtandi
nilutamide	Nilandron